Professor of Urology, Wayne State University
Urology
Dr. Michael L. Cher, MD
|
|
Give Review
Doctor Michael L. Cher, MD works in the field of Urology. He graduated from Washington University School of Medicine in St. Louis. He received awards:"Regional Top Doctor" and "Super Doctor". Dr. Michael L. Cher is a published doctor and has 90 publications published. The lastest was: 'Limited role of radionuclide bone scintigraphy in patients with prostate specific antigen elevations after radical prostatectomy.' He is registered with Medicare and accepts Medicare payments.
Publications
- Variation in the use of postoperative radiotherapy among high-risk patients following radical Prostatectomy.
- Michigan Urological Surgery Improvement Collaborative: Patterns of Care in the Radiographic Staging of Men with Newly Diagnosed Low Risk Prostate Cancer.
- Cryotherapy with Concurrent CpG Oligonucleotide Treatment Controls Local Tumor Recurrence and Modulates HER2/neu Immunity.
- Bone-induced c-kit expression in prostate Cancer: a driver of intraosseous tumor growth.
- Transcriptional Regulation of CXCR4 in Prostate Cancer: Significance of TMPRSS2-ERG Fusions.
- Loss of Let-7 Up-Regulates EZH2 in Prostate Cancer Consistent with the Acquisition of Cancer Stem Cell Signatures That Are Attenuated by BR-DIM.
- PTEN Regulates PDGF Ligand Switch for ?-PDGFR Signaling in Prostate Cancer.
- Cediranib inhibits both the intraosseous growth of PDGF D-positive prostate Cancer cells and the associated bone reaction.
- Primary full-gland Prostate cryoablation in older men (> age of 75 years): results from 860 patients tracked with the COLD Registry.
- Circulating tumor cells: finding the needle in the haystack.
- Shedding of RANKL by tumor-associated MT1-MMP activates Src-dependent prostate Cancer cell migration.
- Androgens Induce Functional CXCR4 through ERG Factor Expression in TMPRSS2-ERG Fusion-Positive Prostate Cancer Cells.
- Phase II trial of capecitabine and weekly docetaxel for metastatic castrate resistant prostate Cancer.
- Bone marrow stromal cells enhance prostate Cancer cell invasion through type I collagen in an MMP-12 dependent manner.
- Platelet-derived growth factor-D overexpression contributes to epithelial-mesenchymal transition of PC3 prostate Cancer cells.
- CXCL12/CXCR4 transactivates HER2 in lipid rafts of prostate Cancer cells and promotes growth of metastatic deposits in bone.
- Proteases, growth factors, chemokines, and the microenvironment in prostate Cancer bone metastasis.
- Prostate Cancer-associated membrane type 1-matrix metalloproteinase: a pivotal role in bone response and intraosseous tumor growth.
- Heterogeneous activation of MMP-9 due to prostate Cancer-bone interaction.
- Quantitative assessment of small intraosseous prostate Cancer burden in SCID mice using fluorescence imaging.
- Lycopene and soy isoflavones in the treatment of prostate Cancer.
- Inhibition of human prostate Cancer growth, osteolysis and angiogenesis in a bone metastasis model by a novel mechanism-based selective gelatinase inhibitor.
- Antitumor and antimetastatic activities of docetaxel are enhanced by genistein through regulation of osteoprotegerin/receptor activator of nuclear factor-kappaB (RANK)...
- Cancer interaction with the bone microenvironment: a workshop of the National Institutes of Health Tumor Microenvironment Study Section.
- Maspin retards cell detachment via a novel interaction with the urokinase-type plasminogen activator/urokinase-type plasminogen activator receptor system.
- CXCL12/CXCR4 signaling activates Akt-1 and MMP-9 expression in prostate Cancer cells: the role of bone microenvironment-associated CXCL12.
- Cathepsin B and tumor proteolysis: contribution of the tumor microenvironment.
- Matrix metalloproteinase activity and osteoclasts in experimental prostate Cancer bone metastasis tissue.
- Bone microenvironment modulates expression and activity of cathepsin B in prostate Cancer.
- High frequency of allelic losses in high-grade prostate Cancer is associated with biochemical progression after radical prostatectomy.
- Regulation of gene expression and inhibition of experimental prostate Cancer bone metastasis by dietary genistein.
- A potential oncogenic activity of platelet-derived growth factor d in prostate Cancer progression.
- Maspin expression inhibits osteolysis, tumor growth, and angiogenesis in a model of prostate Cancer bone metastasis.
- Ten-year survival after radical prostatectomy: specimen Gleason score is the predictor in organ-confined prostate Cancer.
- Third North American Symposium on Skeletal Complications of Malignancy: summary of the scientific sessions.
- Presence of circulating prostate Cancer cells in African American males adversely affects survival.
- Disease-free survival difference between African Americans and whites after radical prostatectomy for local prostate Cancer: a multivariable analysis.
- Matrix metalloproteinase activity, bone matrix turnover, and tumor cell proliferation in prostate Cancer bone metastasis.
- Prostate Cancer diagnosis, staging and survival.
- Prostate Cancer - Old Problems and New Approaches. (Part II. Diagnostic and Prognostic Markers, Pathology and Biological Aspects).
- Prostate Cancer Old Problems and New Approaches. Part III. Prevention and Treatment.
- PTEN loss mediated Akt activation promotes Prostate tumor growth and metastasis via CXCL12/CXCR4 signaling.
- Tissue inhibitor of metalloproteinase (TIMP)-2 acts synergistically with synthetic matrix metalloproteinase (MMP) inhibitors but not with TIMP-4 to enhance the (Membra...
- Stepwise genetic changes associated with progression of nontumorigenic HPV-18 immortalized human prostate Cancer-derived cell line to a malignant phenotype.
- Membrane type 1-matrix metalloproteinase (MT1-MMP) and MMP-2 immunolocalization in human Prostate: change in cellular localization associated with high-grade prostatic...
- Cellular proliferation and prevalence of micrometastatic cells in the bone marrow of patients with clinically localized prostate Cancer.
- Isochromosome 8q formation is associated with 8p loss of heterozygosity in a prostate Cancer cell line.
- Prospects of immunotherapy for the treatment of Prostate carcinoma--a review.
- Severe combined immunodeficient-hu model of human prostate Cancer metastasis to human bone.
- Chromosomal analysis of Renal angiomyolipoma by comparative genomic hybridization: evidence for clonal origin.
- Limited role of radionuclide bone scintigraphy in patients with Prostate specific antigen elevations after radical Prostatectomy.
- Effect of neoadjuvant androgen deprivation on circulating Prostate cells in the bone marrow of men undergoing radical Prostatectomy.
- Systemic interleukin 2 therapy for human Prostate tumors in a nude mouse model.
- Low frequency epithelial cells in bone marrow aspirates from Prostate carcinoma patients are cytogenetically aberrant.
- Predictors for maximal outcome in patients undergoing salvage surgery for radio-recurrent prostate Cancer.
- A similar pattern of chromosomal alterations in prostate Cancers from African-Americans and Caucasian Americans.
- Allelic imbalance mapping of chromosome 16 shows two regions of common deletion in Prostate adenocarcinoma.
- Accelerated tumor proliferation rates in locally recurrent prostate Cancer after radical prostatectomy.
- A t-statistic for objective interpretation of comparative genomic hybridization (CGH) profiles.
- Smooth-muscle myosin heavy-chain isoform expression in Bladder-outlet obstruction.
- Identification of genetic alterations associated with the process of human experimental colon Cancer liver metastasis in the nude mouse.
- Genetic alterations in untreated metastases and androgen-independent prostate Cancer detected by comparative genomic hybridization and allelotyping.
- Cellular proliferative fraction of metastatic lymph nodes predicts survival in stage D1 (TxN+M0) prostate Cancer.
- Continence in the myelodysplastic patient following enterocystoplasty.
- Transitional cell carcinoma of the Ureteral stump 23 years after radical nephrectomy for adenocarcinoma.
- Mapping of regions of physical deletion on chromosome 16q in prostate Cancer cells by fluorescence in situ hybridization (FISH).
- Cellular proliferation in prostatic adenocarcinoma as assessed by bromodeoxyuridine uptake and Ki-67 and PCNA expression.
- The use and accuracy of cross-sectional imaging and fine needle aspiration cytology for detection of pelvic lymph node metastases before radical Prostatectomy.
- High failure rate associated with long-term follow-up of neoadjuvant androgen deprivation followed by radical prostatectomy for stage C prostatic Cancer.
- Comparative genomic hybridization, allelic imbalance, and fluorescence in situ hybridization on chromosome 8 in prostate Cancer.
- Elevated levels of angiostatin in effusions from patients with malignant disease.
- Increased metastatic potential in human Prostate carcinoma cells by overexpression of arachidonate 12-lipoxygenase.
- Inhibition of alpha(v)beta3 integrin reduces angiogenesis, bone turnover, and tumor cell proliferation in experimental prostate Cancer bone metastases.
- Proliferation of prostate Cancer cells in the bone marrow predicts recurrence in patients with localized prostate Cancer.
- Mechanisms governing bone metastasis in prostate Cancer.
- Differential regulation of matrix metalloproteinase-9, tissue inhibitor of metalloproteinase-1 (TIMP-1) and TIMP-2 expression in co-cultures of prostate Cancer and str...
- Persistence of human vascular endothelium in experimental human prostate Cancer bone tumors.
- Angiogenic and antiangiogenic balance regulates concomitant antitumoral resistance.
- Matrix metalloproteinaes and bone metastasis.
- Allelic loss at 16q23.2 is associated with good prognosis in high grade prostate Cancer.
- Tissue inhibitor of metalloproteinase-3 induces apoptosis in prostate Cancer cells and confers increased sensitivity to paclitaxel.
- Are matrix metalloproteinases relevant therapeutic targets for prostate Cancer bone metastasis?
- C-kit and its ligand stem cell factor: potential contribution to prostate Cancer bone metastasis.
- Prostate Cancer cell-derived urokinase-type plasminogen activator contributes to intraosseous tumor growth and bone turnover.
- Prostate Cancer old problems and new approaches : Part I. epidemiology, incidence and genetic alterations.
- Soy isoflavones in conjunction with radiation therapy in patients with prostate Cancer.
- Epigenetic silencing of miR-34a in human prostate Cancer cells and tumor tissue specimens can be reversed by BR-DIM treatment.
- In vitro and in vivo molecular evidence for better therapeutic efficacy of ABT-627 and taxotere combination in prostate Cancer.
- Host matrix metalloproteinase-9 contributes to tumor vascularization without affecting tumor growth in a model of prostate Cancer bone metastasis.
Schools
Washington University In St Louis School Of Medicine
Dallas Co Hp Parkland Mem
Procedures Preformed
- Cystometry
- Cystotomy
- Cystourethroscopy and Transurethral Resection of Bladder Neck
- Excision of Testicular Lesion
- View All
Conditions Treated
- Bedwetting
- Bladder Cancer
- Bladder Infection
- Bladder Stones
- View All
Doctors Specialties
- Urology
Accepted Insurances
Awards
- Regional Top Doctor
- Super Doctor
Education
-
UCSF -
Washington University School of Medicine in St. Louis
Hospital
-
DMC - Children's Hospital of Michigan -
DMC - Detroit Receiving Hospital -
DMC Harper University Hospital
Drug Facts
| NPI NUMBER | 1336187400 | |
| NPPES Provider LastName | CHER | |
| NPPES Provider FirstName | MICHAEL | |
| NPPES Provider ZIPCode | 482012013 | |
| NPPES Provider State | MI | |
| Specialty Description | Urology | |
| Total Claim Count | 441.0 | |
| Distinct Opioid Count | 1.0 | |
| Opioid Claim Count | 17.0 | |
| Percent Opioid Claims | 3.85 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1336187400 |
| Last Name Of The Provider | CHER |
| First Name Of The Provider | MICHAEL |
| View All |
Similar Doctors
|
|
Dr. William G. Nutting, MD
 This Doctor is OpenDoctor Recommended.
|
|
Dr. Stephen A. Liroff, MD |
|
|
Dr. Henry M. Domzalski, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Piyush K. Agarwal, MD |
|
|
Dr. James M. McMurtry, MD |
|
Dr. David A. Burks, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ajay K. Singla, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jorge R. Torriglia, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Priyanka Arshanapalli, MD |
|
|
Dr. Wassim M. Bazzi, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Steven M. Lucas, MD |
|
|
Dr. Aram B. Loeb, MD |
|
|
Dr. Navneet S. Mander, MD |